Myeloma patients: staying connected globally and looking for answers
March 24, 2016
Myeloma patients: staying connected globally and looking for answersWRITTEN BY: Brian GM Durie MD
The bombings in Brussels made this a tough week for the global community, but President Obama pressed ahead with his historic visit to Cuba. In his speech on Tuesday, he cited examples of past medical collaborations between our two countries, such as the work of Dr. Carlos Finlay in Cuba, which helped Dr. Walter Reed learn how to combat yellow fever, as well as more recent joint efforts to fight Ebola in West Africa.
By coincidence, Tampa [Florida] Myeloma Support Group founder Jim Barth and his wife were also in Cuba this past week. They met with Dr. Martha Osario at the National Institute of Oncology and had discussions regarding standards of myeloma care in Cuba. They also introduced her to the services provided by the IMF. Both IMF and ASH publications were provided and appreciated: clearly the beginning of mutual support and collaboration.
You may have also noticed the announcement that Cuba has developed a lung cancer vaccine in a joint venture between Dr. Kelvin Lee at Buffalo’s Roswell Park Cancer Institute and Havana’s Center for Molecular Immunology, the culmination of a 25-year research project. Wonderful Cuban cigars have unfortunately contributed to lung cancer as the 4th leading cause of death in Cuba. This is potentially important for myeloma because the vaccine is against epidermal growth factor (EGF), which is also a growth factor for myeloma. So this vaccine approach, and even this specific EGF target, may prove valuable for myeloma.
Immune therapy updates
It has been a busy week for myeloma immune therapy updates. Vice President Joe Biden visited the Fred Hutchinson Cancer Research Center on Monday to discuss the White House’s $1-billion cancer “moonshot.” Yet again, the focus was on immune approaches, especially CAR-T cell therapy. A Seattle-based patient, Bard Richmond, diagnosed with aggressive myeloma in 2014, met with the Vice President and no doubt conveyed the very personal message of need in his own situation. The laboratory of Dr. Stan Riddell is making dramatic progress with the engineered T-cell immune therapy approach.
In further news, Johnson & Johnson announced a collaboration with Roche to test the combination of the recently approved anti-CD38 monoclonal antibody, Darzalex®, with Atezolizumab (anti-PDL1) for relapsed myeloma. This “all-immune” combination is an exciting new option. Additional studies will include combinations with Revlimid® and pomalidomide (Pomalyst®). Although it will take time to conduct these trials and assess the ultimate role of these new combinations, this rapid progress is truly exciting for the myeloma community.
As I mentioned last week, it would be great if we had rapid guidance from a parallel universe to sort out all our questions and concerns quickly. A fun story in the New York Times suggests that maybe parrots can help us out. Researchers say that parrots easily rival apes and dolphins in all-around “braininess” and resourcefulness. Irene Pepperberg, who studies animal cognition at Harvard University, calls parrots “feathered primates.” They are especially good at sorting out combinations and sequences. Hmm…sounds like a familiar problem!
The good news is that we have so much new to sort out.
As usual, I will keep you posted on progress!
From the IMF Newsroom
This comprehensive review summarizes the current consensus guidelines for myeloma treatment, tailored to match presence of high-risk features. (Paywall; patient access.)
This analysis indicates that the hormone adiponectin may protect against myeloma growth and how low levels can possibly increase risk. (Paywall; patient access.)
This very helpful update demonstrates the long-term benefit of pomalidomide. (Paywall.)
This new formulation of melphalan for intravenous use (for example, with ASCT) has reduced renal and cardiac side effects. (Paywall.)
Dr. Durie sincerely appreciates and reads all comments left here. However, he cannot answer specific medical questions and encourages readers to contact the trained IMF InfoLine staff instead. Specific medical questions posted here will be forwarded to the IMF InfoLine. Questions sent to the InfoLine are answered with input from Dr. Durie and/or other scientific advisors and IMWG members as appropriate, but will not be posted here. To contact the IMF InfoLine, call 800-452-CURE, toll-free in the US and Canada, or send an email to email@example.com. InfoLine hours are 9 am to 4 pm PT. Thank you.